



## EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-49738167/68 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Site: [www.ebnl.org](http://www.ebnl.org)

Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

EBN/2020/S-2512

February 7, 2020

Dept. of Corporate Services  
BSE Ltd  
25<sup>th</sup> floor, New Trading Ring, Rotunda Bldg  
Phiroze Jeejebhoy Towers, Dalal Street  
Fort, Mumbai – 400 001.  
Fax No. 22723121 Email ID: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

Dear Sir,

Ref: Company Code No. 524768  
Sub: Outcome of the Board Meeting.

Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its meeting held today at 2.00 pm, have approved and taken on record the Un-Audited Financial Results of the Company for the Quarter / Nine Months ended December 31, 2019. Also taken on record was the Limited Review Report of M/s. V. Sankar Aiyar & Co., Chartered Accountants [Statutory Auditors] on the above Un-Audited Financial Results. The Certificate of CEO and CFO in terms of Regulation 33 of SEBI (LODR) Regulations, 2015 in respect of the above results was placed before the Board of Directors.

We are attaching herewith the following for your records.

1. Un-Audited Financial Results for the Quarter / Nine months ended December 31, 2019.
2. Limited Review dated February 7, 2020.

The above results were reviewed by the audit committee of the Board of Directors. We are filing the results online in CASF and in XBRL format.

This is for your information and record.

Thanking you,

Yours faithfully,  
For Emmessar Biotech & Nutrition Ltd

Compliance Officer  
Attachment: As above.



*Data Saved*  
*Ref. No. 1458333 dt. 07/02/2020 @ 3.49pm*  
*XBRL*

**EMMESSAR BIOTECH & NUTRITION LTD**

Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State

CIN: L24110MH1992PLC06594229

**UNAUDITED FINANCIAL RESULTS AS ON 31st DECEMBER 2019**

Rs. In Lakhs)

Particulars	Unaudited					Audited year ended
	Quarter Ended			Nine months Ended		
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
I Revenue from Operations	59.28	5.71	28.38	253.55	47.68	62.95
II Other Income	38.06	35.78	31.58	109.22	94.13	129.99
III <b>Total Income (I + II)</b>	<b>97.34</b>	<b>41.49</b>	<b>59.96</b>	<b>362.77</b>	<b>141.81</b>	<b>192.94</b>
IV Expenses						
Cost of material consumed	58.07	0.68	0.81	121.95	3.89	36.60
Purchase of Stock-trade	0.81	0.39	6.15	13.42	10.65	17.95
Change in Inventories of Finished goods	(40.84)	2.50	3.85	(4.52)	3.92	-42.14
Employee Benefit Expenses	17.61	13.43	16.14	44.68	46.97	57.55
Depreciation & Amortisation of Assets	1.45	1.45	2.15	4.34	6.46	7.86
Other Expenditure	36.39	5.91	13.35	101.95	30.58	57.07
<b>Total Expenses (IV)</b>	<b>73.49</b>	<b>24.36</b>	<b>42.45</b>	<b>281.82</b>	<b>102.47</b>	<b>134.89</b>
V Profit / (loss) from Operations before tax (III - IV)	23.85	17.13	17.51	80.95	39.34	58.05
VI Exceptional Items	0.00	0.00	0.00	0.00	0.00	28.67
VII Profit / (loss) before Tax	23.85	17.13	17.51	80.95	39.34	29.38
VIII Tax Expense	-	-	-	-	-	-
1. Current Tax (MAT)	0.00	0.00	0.00	0.00	0.00	-6.00
2. Deferred Tax	0.00	0.00	0.00	0.00	0.00	1.91
3. MAT Credit						28.00
IX Net Profit / (loss) after tax (V - VI)	<b>23.85</b>	<b>17.13</b>	<b>17.51</b>	<b>80.95</b>	39.34	<b>53.29</b>
X Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.96
XI Total comprehensive income and Other Comprehensive Income	23.85	17.13	17.51	80.95	39.34	52.33
XII Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61	499.61
(Face Value of the share)	10.00	10.00	10.00	10.00	10.00	10.00
Earning per Shares						
Basic	0.48	0.34	0.35	1.62	0.79	1.05
Diluted	0.48	0.34	0.35	1.62	0.79	1.05

Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 7th February 2020 and have been subject to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The Company operates three segments i.e. Healthcare, Fine Chemicals and Rent on leasehold land during this quarter.
- Deferred tax & provision for taxation will be calculated annually.
- No Investors Complaint received during the quarter ended 31st December 2019

Mumbai  
7th February 2020

By order of the Board  
MSR Ayyangar  
Managing Director  
DIN: 00090266



EMMESSAR BIOTECH & NUTRITION LIMITED							
Regd Office: T-3/2, MIDC, Taloja-410208, Raigad District, Maharashtra State							
CIN: L24110MH1992PLC06594229							
Segmentwise Revenue, Results and Capital Employed for the Quarter and Nine Months Ended 31st Dec 2019							
Sr. No	Particulars	Unaudited				Audited	
		Quarter Ended			Nine Months ended		Year Ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
1	<b>Segment Revenue</b>						
a	Healthcare	5.43	3.60	28.38	50.99	47.68	51.40
b	Fine Chemicals	53.85	2.11	0.00	202.56	0.00	11.55
c	Rent on leasehold land	33.78	33.78	30.71	101.35	92.13	125.92
d	Others	4.28	2.00	0.87	7.87	2.00	4.08
	<b>Total:</b>	<b>97.34</b>	<b>41.49</b>	<b>59.96</b>	<b>362.77</b>	<b>141.81</b>	<b>192.95</b>
	<b>Less: Inter Segment Revenue</b>	-	-	-	-	-	-
	<b>Net Sales / Income from Operations</b>	<b>97.34</b>	<b>41.49</b>	<b>59.96</b>	<b>362.77</b>	<b>141.81</b>	<b>192.95</b>
2	<b>Segment Results (Profit / Loss) before tax</b>						
a	Healthcare	3.10	2.00	17.23	33.70	28.08	29.21
b	Fine Chemicals	8.44	0.03	0.00	13.97	0.00	0.32
c	Rent on leasehold land	33.36	33.55	30.29	100.09	90.87	125.92
d	Others	4.28	2.00	0.87	7.87	2.00	4.08
	<b>Total:</b>	<b>49.18</b>	<b>37.58</b>	<b>48.39</b>	<b>155.63</b>	<b>120.95</b>	<b>159.53</b>
	<b>Less:</b>						
	Interest	-	-	-	-	-	-
	Other Unallocable Expenditure (net off)	25.33	20.45	30.88	74.68	81.61	130.15
	<b>Total Profit before Tax</b>	<b>23.85</b>	<b>17.13</b>	<b>17.51</b>	<b>80.95</b>	<b>39.34</b>	<b>29.38</b>
3	<b>Capital Employed</b>						
	<b>(Segment Assets - Segment Liabilities)</b>						
a	Healthcare	6.42	7.30	6.43	6.42	6.43	7.97
b	Fine Chemicals	36.88	9.55	72.99	36.88	72.99	71.51
c	Rent on leasehold land	2.59	2.55	2.46	2.59	2.46	3.01
d	Others	231.32	192.49	210.48	231.32	210.48	179.41
	<b>Total:</b>	<b>277.21</b>	<b>211.89</b>	<b>292.36</b>	<b>277.21</b>	<b>292.36</b>	<b>261.90</b>

**Note:** The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 7th February, 2020.

Mumbai  
7th February 2020

By order of the Board  
MSR Ayyangar  
Managing Director  
DIN: 00090266



Tel. : 2200 4465, 2206 7440  
Fax : 91-22-2200 0649  
E-mail : mumbai@vsa.co.in  
Website : www.vsa.co.in

**V. Sankar Aiyar & Co.**  
CHARTERED ACCOUNTANTS  
2-C, Court Chambers  
35, New Marine Lines  
Mumbai - 400 020

**LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS  
FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER 2019.**

The Board of Directors  
Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited financial results of Emmessar Biotech & Nutrition Limited ("the Company") for the quarter and nine months ended 31<sup>st</sup> December, 2019 (the Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIT/CFD/FAC/62/2016 dated 5th July 2016. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Agreement and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No: CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai  
Date: February 7<sup>th</sup>, 2020

For V. Sankar Aiyar & Co.  
Chartered Accountants  
Firm Regn. No.109208W



(V. Mohan)  
Partner  
Membership No.17748  
UDIN: 20017748AAAAAN2473